Delivery Order SPE2DB22D3401-SPE2DB25FT4NL
- Not listed
- The Defense Logistics Agency awarded a $27,728.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL units). The contract, which is a non-set-aside competitive award with an ultimate completion date of June 3, 2025, represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency (DLA) awarded a $20,272.36 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. No set-aside designation was applied...
- The Defense Logistics Agency awarded a delivery order valued at $11,105.00 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a single shipment of pharmaceutical product to support federal medical procurement needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $41,611.76 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on April 23, 2025, with a completion date of April 24, 2025. This competitive award, issued under a firm fixed-price delivery order contract with no set-aside designation, represents a pharmaceutical supply transaction supporting federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 mL pens totaling $20,114.60 with completion scheduled for July 22, 2025. This competitive, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded a delivery order valued at $7,656.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on August 18, 2025, with completion scheduled for August 19, 2025. This non-set-aside, competitively awarded contract operates under a firm fixed price arrangement and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a $25,054.58 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitive, non-set-aside contract represents a firm fixed price delivery order with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis,...
- The Defense Logistics Agency awarded a $34,661.18 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitively awarded, firm fixed-price contract has an ultimate completion date of August 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order valued at $16,700.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 20, 2025, with a completion date of August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed-price pricing and represents a single delivery order executed under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $19,081.06 for Dupixent 300 mg/2 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a single delivery transaction under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be performed at the vendor's location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT4NLDelivery Order
The Defense Logistics Agency awarded a $25,953.24 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 12, 2025, for the supply of Dupixent 300 mg/2 ml pens (2 ml quantity). This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 13, 2025. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. Dupixent, a biologic immunosuppressant used primarily for eczema, asthma, and chronic rhinosinusitis, represents one component of the broad pharmaceutical portfolio delivered under this strategic contract vehicle, which supports the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.0k | 6/12/25 |